Friday, 10 July 2009

Glucare




Glucare may be available in the countries listed below.


Ingredient matches for Glucare



Metformin

Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Glucare in the following countries:


  • Oman

International Drug Name Search

Posted by at No comments:
Labels:

Thursday, 9 July 2009

Zomig




In the US, Zomig (zolmitriptan systemic) is a member of the drug class antimigraine agents and is used to treat Cyclic Vomiting Syndrome and Migraine.

US matches:

  • Zomig

  • Zomig Spray

  • Zomig ZMT Disintegrating Tablets

  • Zomig nasal

  • Zomig-ZMT

  • Zomig Nasal Spray

UK matches:

  • Zomig Tablets 2.5mg
  • Zomig 5mg Nasal Spray
  • Zomig Rapimelt 2.5mg
  • Zomig Rapimelt 5mg Orodispersible Tablets
  • Zomig Tablets 2.5mg (SPC)
  • Zomig 5mg Nasal Spray (SPC)
  • Zomig Rapimelt 2.5mg (SPC)
  • Zomig Rapimelt 5 mg Orodispersible Tablets (SPC)

Ingredient matches for Zomig



Zolmitriptan

Zolmitriptan is reported as an ingredient of Zomig in the following countries:


  • Aruba

  • Australia

  • Austria

  • Bahamas

  • Barbados

  • Belgium

  • Bermuda

  • Brazil

  • Canada

  • Costa Rica

  • Croatia (Hrvatska)

  • Czech Republic

  • Denmark

  • Dominican Republic

  • El Salvador

  • Estonia

  • Finland

  • France

  • Georgia

  • Ghana

  • Guatemala

  • Haiti

  • Hong Kong

  • Hungary

  • Iceland

  • Ireland

  • Israel

  • Italy

  • Jamaica

  • Japan

  • Kenya

  • Latvia

  • Lithuania

  • Luxembourg

  • Malawi

  • Malta

  • Mexico

  • Mozambique

  • Netherlands

  • Netherlands Antilles

  • Nicaragua

  • Nigeria

  • Norway

  • Oman

  • Panama

  • Philippines

  • Poland

  • Portugal

  • Russian Federation

  • Serbia

  • Singapore

  • Slovakia

  • Slovenia

  • South Africa

  • Spain

  • Sudan

  • Sweden

  • Switzerland

  • Tanzania

  • Thailand

  • Trinidad & Tobago

  • Turkey

  • Uganda

  • United Kingdom

  • United States

  • Zambia

  • Zimbabwe

International Drug Name Search

Glossary

SPC Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.
Posted by at No comments:
Labels:

Vastoran




Vastoran may be available in the countries listed below.


Ingredient matches for Vastoran



Pravastatin

Pravastatin sodium salt (a derivative of Pravastatin) is reported as an ingredient of Vastoran in the following countries:


  • Australia

International Drug Name Search

Posted by at No comments:
Labels:

Wednesday, 8 July 2009

Letairis


Letairis is a brand name of ambrisentan, approved by the FDA in the following formulation(s):


LETAIRIS (ambrisentan - tablet; oral)



  • Manufacturer: GILEAD

    Approval date: June 15, 2007

    Strength(s): 10MG [RLD], 5MG

Has a generic version of Letairis been approved?


No. There is currently no therapeutically equivalent version of Letairis available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Letairis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • 3-(Het) arylcarboxylic acid derivatives, their preparation and intermediates for their preparation
    Patent 5,703,017
    Issued: December 30, 1997
    Inventor(s): Baumann; Ernst & Rheinheimer; Joachim & Vogelbacher; Uwe Josef & Bratz; Matthias & Theobald; Hans & Gerber; Matthias & Westphalen; Karl-Otto & Walter; Helmut & Rademacher; Wilhelm
    Assignee(s): BASF Aktiengesellschaft
    3-(Het)arylcarboxylic acid derivatives of the formula I ##STR1## where R is formyl, CO.sub.2 H or a radical hydrolyzable to COOH and the other substituents have the following meanings: R.sup.2 and R.sup.3 are each halogen, alkyl, haloalkyl, alkoxy, haloalkoxy or alkylthio; X is nitrogen or CR.sup.14, where R.sup.14 is hydrogen or, together with R.sup.3, forms an alkylene or alkenylene chain, in each of which a methylene group is replaced by oxygen; R.sup.4 is phenyl or naphthyl, each of which is unsubstituted or substituted or an unsubstituted or substituted five-membered or six-membered heteroaromatic structure containing one to three nitrogen atoms or one sulfur or oxygen atom; R.sup.5 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, alkoxyalkyl, alkylthioalkyl or phenyl; R.sup.6 is C.sub.1 -C.sub.8 -alkyl, C.sub.3 -C.sub.6 -alkenyl, C.sub.3 -C.sub.6 -alkynyl or C.sub.3 -C.sub.4 -cyclo-alkyl, each of which may be mono- or polysubstituted; Y is sulfur, oxygen or a single bond; and Z is sulfur or oxygen; with the proviso that R.sup.6 is not unsubstituted C.sub.1 -C.sub.4 -alkyl when R.sup.4 is unsubstituted phenyl, Z is oxygen and simultaneously R.sup.5 is methyl or hydrogen.
    Patent expiration dates:

    • December 30, 2014
      ✓ 
      Drug substance




  • Use of carboxylic acid derivatives as drugs
    Patent 5,840,722
    Issued: November 24, 1998
    Inventor(s): Baumann; Ernst & Vogelbacher; Uwe Josef & Rheinheimer; Joachim & Klinge; Dagmar & Riechers; Hartmut & Kroger; Burkhard & Bialojan; Siegfried & Bollschweiler; Claus & Wernet; Wolfgang & Unger; Liliane & Raschack; Manfred
    Assignee(s): BASF Aktiengesellschaft
    A method of inhibiting endothelin receptors by administering to a patient a compound of the formula I ##STR1##
    Patent expiration dates:

    • November 24, 2015
      ✓ 
      Patent use: METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.




  • Carboxylic acid derivatives, their preparation and use
    Patent 7,109,205
    Issued: September 19, 2006
    Inventor(s): Riechers; Hartmut & Klinge; Dagmar & Amberg; Wilhelm & Kling; Andreas & Müller; Stefan & Baumann; Ernst & Rheinheimer; Joachim & Vogelbacher; Uwe Josef & Wernet; Wolfgang & Unger; Liliane & Raschack; Manfred
    Assignee(s): Abbott GmbH & Co. KG
    Carboxylic acid derivatives where R–R6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.
    Patent expiration dates:

    • October 7, 2015
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Carboxylic acid derivatives, their preparation and use
    Patent 7,601,730
    Issued: October 13, 2009
    Inventor(s): Riechers; Hartmut & Klinge; Dagmar & Amberg; Wilhelm & Kling; Andreas & Muller; Stefan & Baumann; Ernst & Rheinheimer; Joachim & Vogelbacher; Uwe Josef & Wernet; Wolfgang & Unger; Liliane & Raschack; Manfred
    Assignee(s): Abbott GmbH & Co. KG
    Carboxylic acid derivatives where R—R6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.
    Patent expiration dates:

    • October 7, 2015
      ✓ 
      Patent use: METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT




  • Carboxylic acid derivatives, their preparation and use
    Patent RE42462
    Issued: June 14, 2011
    Inventor(s): Riechers; Hartmut & Klinge; Dagmar & Amberg; Wilhelm & Kling; Andreas & Muller; Stefan & Baumann; Ernst & Rheinheimer; Joachim & Vogelbacher; Uwe Josef & Wernet; Wolfgang & Unger; Liliane & Raschack; Manfred
    Assignee(s): Abbott GmbH & Co. KG
    Carboxylic acid derivatives where R-R6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.
    Patent expiration dates:

    • October 7, 2015
      ✓ 
      Drug substance



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • June 15, 2012 - NEW CHEMICAL ENTITY

    • June 15, 2014 - ORPHAN DRUG EXCLUSIVITY

See also...

  • Letairis Consumer Information (Drugs.com)
  • Letairis Consumer Information (Wolters Kluwer)
  • Letairis Consumer Information (Cerner Multum)
  • Letairis Advanced Consumer Information (Micromedex)
  • Letairis AHFS DI Monographs (ASHP)
  • Ambrisentan Consumer Information (Wolters Kluwer)
  • Ambrisentan Consumer Information (Cerner Multum)
  • Ambrisentan Advanced Consumer Information (Micromedex)
  • Ambrisentan AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Sunday, 5 July 2009

ProAmatine


ProAmatine is a brand name of midodrine, approved by the FDA in the following formulation(s):


PROAMATINE (midodrine hydrochloride - tablet; oral)



  • Manufacturer: SHIRE LLC

    Approval date: September 6, 1996

    Strength(s): 2.5MG [AB], 5MG [RLD][AB]


  • Manufacturer: SHIRE LLC

    Approval date: March 20, 2002

    Strength(s): 10MG [AB]

Has a generic version of ProAmatine been approved?


Yes. The following products are equivalent to ProAmatine:


midodrine hydrochloride tablet; oral



  • Manufacturer: APOTEX INC

    Approval date: September 12, 2006

    Strength(s): 10MG [AB], 2.5MG [AB], 5MG [AB]


  • Manufacturer: IMPAX PHARMS

    Approval date: May 27, 2004

    Strength(s): 2.5MG [AB], 5MG [AB]


  • Manufacturer: IMPAX PHARMS

    Approval date: December 16, 2005

    Strength(s): 10MG [AB]


  • Manufacturer: MYLAN

    Approval date: September 10, 2003

    Strength(s): 10MG [AB], 2.5MG [AB], 5MG [AB]


  • Manufacturer: SANDOZ

    Approval date: September 11, 2003

    Strength(s): 2.5MG [AB], 5MG [AB]


  • Manufacturer: SANDOZ

    Approval date: July 2, 2004

    Strength(s): 10MG [AB]

ORVATEN (midodrine hydrochloride tablet; oral)



  • Manufacturer: UPSHER SMITH

    Approval date: November 3, 2004

    Strength(s): 10MG [AB], 2.5MG [AB], 5MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of ProAmatine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with ProAmatine.

See also...

  • ProAmatine Consumer Information (Wolters Kluwer)
  • ProAmatine Consumer Information (Cerner Multum)
  • Proamatine Advanced Consumer Information (Micromedex)
  • Midodrine Consumer Information (Wolters Kluwer)
  • Midodrine Consumer Information (Cerner Multum)
  • Midodrine Advanced Consumer Information (Micromedex)
  • Midodrine Hydrochloride AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Celeston Chronodose




Celeston Chronodose may be available in the countries listed below.


Ingredient matches for Celeston Chronodose



Betamethasone

Betamethasone 21-acetate (a derivative of Betamethasone) is reported as an ingredient of Celeston Chronodose in the following countries:


  • Luxembourg

  • Norway

International Drug Name Search

Posted by at No comments:
Labels:

Saturday, 4 July 2009

Vasocidin


Vasocidin is a brand name of prednisolone/sulfacetamide sodium ophthalmic, approved by the FDA in the following formulation(s):


VASOCIDIN (prednisolone sodium phosphate; sulfacetamide sodium - solution/drops; ophthalmic)



  • Manufacturer: NOVARTIS

    Approval date: August 26, 1988

    Strength(s): EQ 0.23% PHOSPHATE;10% [RLD][AT]

Has a generic version of Vasocidin been approved?


Yes. The following products are equivalent to Vasocidin:


SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE (prednisolone sodium phosphate; sulfacetamide sodium solution/drops; ophthalmic)



  • Manufacturer: ALCON PHARMS LTD

    Approval date: May 27, 1993

    Strength(s): EQ 0.23% PHOSPHATE;10% [AT]


  • Manufacturer: BAUSCH AND LOMB

    Approval date: December 29, 1995

    Strength(s): EQ 0.23% PHOSPHATE;10% [AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vasocidin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Vasocidin.

See also...

  • Vasocidin Drops Consumer Information (Wolters Kluwer)
  • Vasocidin Consumer Information (Cerner Multum)
  • Prednisolone/Sulfacetamide Drops Consumer Information (Wolters Kluwer)
  • Prednisolone/Sulfacetamide Ointment Consumer Information (Wolters Kluwer)
  • Prednisolone/Sulfacetamide Suspension Consumer Information (Wolters Kluwer)
  • Sulfacetamide and prednisolone ophthalmic Consumer Information (Cerner Multum)
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)